REG - Diaceutics PLC - Appointment of Nominated Adviser and Broker

DiaceuticsAnnouncement

02/09/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240902:nRSB3993Ca&default-theme=true

RNS Number : 3993C  Diaceutics PLC  02 September 2024

Appointment of Nominated Adviser and Broker

 

Belfast and London, 2 September 2024 - Diaceutics PLC
(https://www.diaceutics.com/) (AIM: DXRX), a leading technology and solutions
provider to the pharma and biotech industry is pleased to announce the
appointment of Canaccord Genuity Limited as the Company's Nominated Adviser
and Broker, with immediate effect.

 

Enquiries:

 Diaceutics PLC  
 Ryan Keeling, Chief Executive Officer              Tel: +44 (0)28 9040 6500

 Nick Roberts, Chief Financial Officer              investorrelations@diaceutics.com (mailto:investorrelations@diaceutics.com)

 Canaccord Genuity Limited (Nomad & Broker)         Tel: +44 (0)20 7523 8000
 Simon Bridges, Andrew Potts, Harry Rees

 Alma Strategic Communications                      Tel: +44(0)20 3405 0205
 Caroline Forde, Kinvara Verdon                     diaceutics@almastrategic.com

 

About Diaceutics

At Diaceutics we believe that every patient should get the opportunity to
receive the right test and the right therapy to positively impact their
disease outcome.

 

We provide the world's leading pharma and biotech companies with an end-to-end
commercialisation solution for precision medicines through data analytics,
scientific and advisory services enabled by our platform DXRX - The
Diagnostics Network ®.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  APPZZGFRVGNGDZM